KBLBOTCPlastic Material, Synth Resin/Rubber, Cellulos (No Glass)Fiscal year ends December 31

Kraig Biocraft Laboratories, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.08−0.00 (-4.70%)

Close on Oct 19, 2026

Market cap: $90.05M
P/E (TTM): –
Dividend yield: –

Kraig Biocraft Laboratories, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	–	–	–	–	–	–	–	0.40	0.10	0.03	0	0	0	0	0	–	–	–	–
Research & Development	0.17	0.16	0.24	0.18	0.20	0.09	0.22	0.15	0.26	0.40	0.43	0.44	0.49	0.47	0.25	0.14	–	–	–
General & Administrative	1.96	1.75	1.45	0.83	1.50	3.52	1.41	0.52	1.22	1.74	0.92	0.90	1.31	0.38	0.79	0.59	–	–	–
Advertising Expenses	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	3.37	3.07	2.61	2.12	2.76	4.53	2.62	1.36	2.25	2.98	2.05	1.83	2.21	1.56	1.30	1.29	–	–	–
Operating Income	-3.37	-3.07	-2.61	-2.12	-2.76	-4.53	-2.62	-0.96	-2.16	-2.95	-2.05	-1.83	-2.21	-1.56	-1.30	-1.29	–	–	–
Interest Expense	0.57	0.53	0.48	0.15	0.24	0.01	0.29	0.23	0.18	0.14	0.10	0.07	0.07	0.05	0	0.05	–	–	–
Interest & Investment Income	–	–	–	–	–	–	0.01	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.25	-0.32	-0.41	-1.72	-5.29	-0.44	-0.29	-0.21	-0.18	-0.13	-0.08	-0.04	-5.25	-0.04	0.00	-0.50	–	–	–
Asset Impairment Charges	–	–	0.10	–	–	–	–	0	0	0	0	0	0	0	0	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	-0.05	0	–	–	–	0	0.00	0	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	0	-5.19	0	–	–	–	–	–
Pretax Income	-3.62	-3.40	-3.03	-3.84	-8.05	-4.97	-2.91	-1.17	-2.33	-3.07	-2.13	-1.87	-7.47	-1.60	-1.30	-1.78	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	0	0	0	0	0	0	0	0	–	–	–	–
Net Income	-3.62	-3.40	-3.03	-3.84	-8.05	-4.97	-2.91	-1.17	-2.33	-3.07	-2.13	-1.87	-7.47	-1.60	-1.30	-1.78	-1.43	-1.72	-0.47
EPS (Basic)(per share)	0.00	0.00	0.00	0.00	-0.01	-0.01	0.00	0.00	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	–	–	–
EPS (Diluted)(per share)	0.00	0.00	0.00	0.00	-0.01	-0.01	0.00	0.00	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	1,059	1,038	1,033	974	878	849	836	817	791	744	686	662	616	596	573	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	1,059	1,038	1,033	974	878	849	836	817	791	744	686	662	616	596	573	–	–	–	–
EBITDA	–	–	–	–	–	–	–	-0.93	-2.14	-2.93	-2.04	-1.83	-2.21	-1.55	-1.29	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 44.9%

Financial strength

Current ratio: 0.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 31.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –